Latest news with #SrinivasSadu
Business Standard
5 days ago
- Business
- Business Standard
Gland Pharma gains after Q1 PAT climbs 50% YoY to Rs 215 cr
Gland Pharma advanced 1.36% to Rs 1,991.15 after the company's consolidated net profit surged 49.88% to Rs 215.48 crore in Q1 FY26 as against Rs 143.76 crore posted in Q1 FY25. Revenue from operations increased by 7.41% YoY to Rs 1,505.62 crore for the quarter ended 30 June 2025. Profit before tax (PBT) stood at Rs 312.74 crore in Q1 FY26, up 43.29% from Rs 218.25 crore recorded in Q1 FY25. EBITDA for the quarter came in at Rs 367.8 crore, marking a 38.58% growth YoY. The EBITDA margin improved to 24%, compared to 19% in the same period last year. On the geographical revenue front, Revenue from the US market stood at Rs 744.3 crore (down 2.42% YoY), revenue from Europe was at Rs 330.2 crore (up 28.68% YoY), Canada, Australia, and New Zealand stood at Rs 73.9 crore (up 65.32% YoY), Revenue from India was at Rs 59.4 crore (up 12.71% YoY) and the rest of the world was at Rs 297.8 crore (up 4.52% YoY) during the period under review. Total capex for the quarter rose 23.39% to Rs 78.6 crore in Q1 FY26, compared to Rs 63.7 crore in the same period last year. The companys total R&D expenses were Rs 46 crore in Q1 FY26, representing 4.4% of revenue. During Q1 FY26, the company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (in three new strengths), Liraglutide, and Acetaminophen Bags. Additionally, one ANDA (Abbreviated New Drug Application) was filed and nine were approved in Q1 FY26, contributing to a cumulative total of 372 ANDA filings in the U.S. (325 approved, 47 pending). Srinivas Sadu, Executive Chairman of Gland Pharma, said, We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships. We're committed to building on this strong foundation, improving our performance, and reinforcing Gland's path toward sustainable growth Shyamakant Giri, CEO, Gland Pharma, said, This quarters performance, with improved margins and Cenexi achieving EBITDA break even, reinforces the progress we are making in delivering our long-term vision. By enhancing our base business, investing in differentiated products, and driving operational efficiencies, we are positioning ourselves for sustained growth. At the same time, our continued focus on R&D, adherence to global quality standards, and investment in capability building position us to scale further, tap new markets, and deliver long-term value. Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Gland Pharma Q1 profit jumps 50% on core growth, Cenexi turnaround
Hyderabad-based Gland Pharma reported a 50 per cent increase in its consolidated net profit year-on-year (Y-o-Y), reaching ₹215 crore for the first quarter of the financial year (Q1FY26). Revenue from operations rose 7 per cent Y-o-Y to ₹1,505 crore. The growth was driven by robust performance in its core business and a successful turnaround at Cenexi, a French pharmaceutical contract development and manufacturing organisation (CDMO) specialising in sterile injectable and lyophilised drug products, which Gland Pharma acquired in 2023. Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent. 'We're off to a positive start this year with growth in revenue and a jump in profitability. Our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships,' said Srinivas Sadu, executive chairman, Gland Pharma. 'By enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth. Our focus on adherence to global quality standards and investment in capability building position us to scale further, tap new markets and deliver long-term value,' said Shyamakant Giri, chief executive officer, Gland Pharma. During the quarter, research and development (R&D) expenses stood at ₹46 crore, accounting for 4.4 per cent of revenue. The company launched 12 new molecules in regulated markets, including Colistimethate, Epinephrine, Vancomycin (three new strengths), Liraglutide and Acetaminophen bags. One abbreviated new drug application (ANDA) was filed and nine were approved during the quarter, bringing cumulative US ANDA filings to 372 (325 approved and 47 pending). Its in-house complex pipeline saw six product launches, with three more awaiting approval. Complex injectables remain a key driver of long-term growth, with more products being added to the pipeline. Fifteen products are in co-development (seven under the 505(b)(2) pathway and eight ANDAs), with commercialisation expected to begin in FY28. One ready-to-use (RTU) infusion bag was filed this quarter, bringing the total RTU product filings in the US to 20 (14 approved). Another 10 are in development, targeting a $767 million market. The company expanded its GLP-1 portfolio, launching Liraglutide in the UK and Australia, and is increasing GLP-1/pen/cartridge capacity from 40 million to 140 million units. It also received a good manufacturing practice (GMP) compliance certificate from the Danish Medicines Agency for aseptically prepared powder for injection, infusion and inhalation. The results were announced after market hours. Gland Pharma's stock fell by 0.95 per cent, ending the day's trade at ₹1,962.30 per share on the BSE.
The Hindu
5 days ago
- Business
- The Hindu
Gland Pharma Q1 net surges 50% to ₹216 crore
Gland Pharma reported consolidated net profit rose nearly 50% for the June quarter to ₹215.5 crore from the ₹143.8 crore a year earlier as revenue from all but the key U.S. market increased. The higher net profit came on a more than 7% increase in the revenue from operations to ₹1,505.6 crore (₹1,401.7 crore). Market wise performance numbers showed the Hyderabad-based generic injectable-focused company's revenue from the U.S. declined 2% to ₹744.3 crore (₹762.8 crore). Sales to Canada, Australia and New Zealand (Other Core Markets) increased 65% to ₹73.9 crore (₹44.7 crore), while revenue from Europe went up 29% ₹330.2 crore (₹256.6 crore). In India, sales rose 13% to ₹59.4 crore (₹52.7 crore). Revenue from the Rest of World market increased 5% to ₹297.8 crore (₹284.9 crore). A strong performance in the company's base business and a turnaround at Cenexi, the French firm that Gland acquired a few years ago, were behind the revenue growth and jump in profitability, Executive Chairman Srinivas Sadu said. 'These results show our strategic priorities are progressing. We are strengthening our capabilities, adding new capacity and boosting research and development with complex products and key partnerships,' he said in a release. CEO Shyamakant Giri said, 'by enhancing our base business, investing in differentiated products and driving operational efficiencies, we are positioning ourselves for sustained growth.'
Business Upturn
6 days ago
- Business
- Business Upturn
Gland Pharma Q1 Results: Revenue surges 7% YoY to Rs 1,505.6 crore, net profit up 50% YoY
Gland Pharma posted a robust set of Q1 FY26 results, showcasing significant year-on-year growth across revenue, margins, and profitability. The company's revenue from operations stood at ₹1,505.6 crore in Q1 FY26, up 7% from ₹1,401.7 crore in Q1 FY25. This growth was supported by better product mix and operational expansion. Gross profit rose to ₹984.5 crore, marking an 18% YoY increase compared to ₹837.5 crore last year. The gross margin improved to 65%, up from 60% a year ago. EBITDA jumped 39% YoY to ₹367.8 crore, from ₹265.4 crore in Q1 FY25. The EBITDA margin expanded to 24%, gaining 549 basis points (bps) YoY. Adjusted EBITDA, which includes employee stock option expenses, came in at ₹373.7 crore, up 41% YoY. The adjusted EBITDA margin improved to 25%, up 589 bps YoY. Profit before tax (PBT) increased 43% YoY to ₹312.7 crore, up from ₹218.2 crore in the same quarter last year. The company's net profit (PAT) rose sharply by 50% YoY, reaching ₹215.5 crore, compared to ₹143.8 crore in Q1 FY25. The PAT margin improved to 14%, from 10% YoY—a gain of 405 bps. Commenting on the results, Srinivas Sadu, Executive Chairman of Gland Pharma, stated, 'We're off to a positive start this year with a growth in revenue and a significant jump in profitability, which was driven by a strong performance in our base business and a turnaround at Cenexi. These results show our strategic priorities are progressing and we are strengthening our capabilities, adding new capacity, and boosting R&D with complex products and key partnerships. We're committed to building on this strong foundation, improving our performance, and reinforcing Gland's path toward sustainable growth Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
